

# REVANCE<sup>®</sup>

## Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

August 2, 2022

*Conference Call Scheduled for Tuesday, August 9, 2022 at 4:30 p.m. ET.*

NASHVILLE, Tenn.--(BUSINESS WIRE)--Aug. 2, 2022-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.

Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company's website at: [www.revance.com](http://www.revance.com).

To access the call by phone, please use this registration [link](#), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A webcast replay will be available in the investor relations section on the company's website for 30 days following the completion of the call.

### **About Revance Therapeutics, Inc.**

Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting neuromodulator product, DaxibotulinumtoxinA for Injection. Revance has successfully completed Phase 3 clinical programs for DaxibotulinumtoxinA for Injection in glabellar (frown) lines, for which the company is currently pursuing U.S. regulatory approval, and in cervical dystonia. Revance is also evaluating DaxibotulinumtoxinA for Injection in adult upper limb spasticity. Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the OPUL™ Relational Commerce Platform. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic. For more information or to join our team visit us at [www.revance.com](http://www.revance.com).

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

BOTOX® is a registered trademark of Allergan, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220802005975/en/): <https://www.businesswire.com/news/home/20220802005975/en/>

### **Media**

Revance Therapeutics, Inc.:

Sara Fahy

[Media@revance.com](mailto:Media@revance.com)

### **Investors**

Revance Therapeutics, Inc.:

Jessica Serra, 626-589-1007

[jessica.serra@revance.com](mailto:jessica.serra@revance.com)

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

[laurence@gilmartinir.com](mailto:laurence@gilmartinir.com)

Source: Revance Therapeutics, Inc.